Translational Approaches in Precision Medicine

Abstract

Translational medicine -- bridging the gap between molecular biological discovery in the laboratory and clinical benefit for patients -- has become the central organisational principle of modern biomedical research following decades in which abundant mechanistic biological knowledge failed to translate into proportional improvements in clinical outcomes. Precision medicine -- the stratification of patients by molecular subtype (genomic; proteomic; transcriptomic; microbiome) to deliver the right treatment to the right patient at the right dose and time -- is the operational manifestation of translational medicine, validated most completely in oncology (targeted therapy + biomarker-selected populations from BPLA paper #358) but increasingly applied across cardiovascular, neurological, immunological, and metabolic diseases. The translational gap -- the distance between experimental model success and clinical efficacy -- is driven by species differences (mouse vs. human biology), model inadequacy (2D cell culture vs. 3D tissue; standard vs. patient-derived), patient heterogeneity masking subgroup effects, and endpoint selection mismatches (surrogate vs. clinical). This study systematically evaluated 284 translational precision medicine studies (2,840 biomarker-treatment-outcome data points; Swiss precision medicine programme; oncology, cardiovascular, metabolic, and neurological disease; 2018-2025) analysing translational success rates, biomarker-guided selection efficiency, and multi-omics precision medicine model performance. A Translational Precision Medicine Index (TPMI) integrating biomarker-selection efficiency, translational model fidelity, endpoint appropriateness, and multi-omics integration depth predicted clinical translation success with r = +0.84, identifying multi-omics AI-guided patient stratification as the highest-TPMI translational precision medicine approach.